Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Alvotech

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

Fuji Pharma

Shinhan Capital

Alvogen

Athos Capital

Aztiq

Aztiq Pharma

Baxter Ventures

Happy International Day of Women and Girls in Science! Women and girls represent half of the world’s population, but remain underrepresented in Science, Technology, Engineering and Mathematics, the STEM fields. Alvotech has achieved and strives to maintain gender balance in its workforce. Diversity increases the pool of talent , brings in fresh perspectives, and creativity. #womeninscience #equality #diversity #STEM

We are so happy to announce that Tanya Zharov, Alvotech’s Chief Legal Counsel, has been awarded the Icelandic Association of Businesswomen’s (FKA) highest honor, in recognition of extraordinary personal achievement and acts of inspiration for other women.

Congratulations also to the recipients of FKA's encouragement and gratitude awards, Inga Tinna Sigurðardóttir, founder of Dineout and Guðlaug Rakel Guðjónsdóttir, Managing Director of Sudurnes Hospital & Health Center. #FKA #WomenInBusiness

We are thrilled to receive European marketing authorization for our ustekinumab biosimilar, which will be marketed by STADA Group in Europe. This is the first ustekinumab biosimilar to be approved by the European Commission. Previously, the biosimilar was also approved in Canada and Japan. We're excited about spearheading biosimilar competition in the ustekinumab market and increasing patient access to biologic therapies! #biosimilars #HealthAccess https://ow.ly/Q50B50QpwCK

Ready for another whirlwind ride around the sun? After this extraordinary year, we can hardly wait! #366days #NewYear #2024

Snow in Reykjavik , the aroma of hot chocolate ☕ and Yule songs 🎅 filling the air. Today's winter solstice heralds longer days. May your holidays be merry and bright.🎄

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover		0.14 -	0.06 56.21%	0.10 62.98%	0.10 3.98%
cash conversion cycle				390.17 -	334.26 14.33%
cash per share		0.13 -	0.07 44.60%	0.34 366.26%	0.05 85.39%
company equity multiplier		-0.55 -	-4.41 706.05%	-1.47 66.71%	-1.02 30.58%
days of inventory outstanding				407.00 -	168.90 58.50%
days of payables outstanding				280.11 -	182.81 34.74%
days of sales outstanding		213.16 -	534.83 150.91%	263.28 50.77%	348.17 32.24%
dividend yield
ebit per revenue	-1.93 -	-2.06 7.24%	-6.40 210.14%	-4.17 34.84%	-3.88 6.99%
ebt per ebit	3.41 -	2.12 37.74%	0.63 70.13%	1.59 151.29%	1.83 15.22%
effective tax rate	-0.00 -	0.42 17,891.26%	0.32 23.38%	0.07 78.41%	0.15 121.07%
enterprise value multiple		-26.83 -	-19.23 28.34%	-8.33 56.68%	-10.98 31.79%
fixed asset turnover		0.38 -	0.18 52.43%	0.31 72.93%	0.26 17.20%
free cash flow per share	-0.40 -	-0.35 10.69%	-1.10 211.56%	-1.83 65.67%	-1.58 13.65%
gross profit margin	1 -	1 0%	1 0%	0.23 77.20%	-0.76 432.95%
interest coverage	-0.64 -	-1.41 119.90%	-2.01 42.17%	-1.84 8.35%	-2.66 44.93%
inventory turnover				0.90 -	2.16 140.97%
long term debt to capitalization		-3.37 -	1.36 140.32%	3.62 166.14%	10.79 198.18%
net income per ebt	1.00 -	0.58 41.86%	0.68 16.73%	0.93 36.84%	0.85 8.97%
net profit margin	-6.58 -	-2.55 61.18%	-2.76 8.14%	-6.19 124.08%	-6.03 2.45%
operating cash flow per share	-0.36 -	-0.30 16.10%	-0.94 207.11%	-1.58 68.71%	-1.37 13.05%
operating cycle				670.28 -	517.06 22.86%
operating profit margin	-1.93 -	-2.06 7.24%	-6.40 210.14%	-4.17 34.84%	-3.88 6.99%
payables turnover				1.30 -	2.00 53.23%
pretax profit margin	-6.56 -	-4.38 33.23%	-4.06 7.36%	-6.64 63.75%	-7.12 7.17%
price fair value		-3.14 -	-20.10 539.50%	-3.50 82.58%	-2.80 20.13%
receivables turnover		1.71 -	0.68 60.14%	1.39 103.14%	1.05 24.38%
return on assets		-0.36 -	-0.17 52.64%	-0.62 265.21%	-0.58 6.33%
return on capital employed		-0.32 -	-0.48 49.12%	-0.52 8.19%	-0.51 1.73%
return on equity		0.20 -	0.75 281.74%	0.91 21.57%	0.59 34.98%
total debt to capitalization		-3.55 -	1.35 137.98%	3.35 147.78%	7.52 124.86%

NASDAQ:ALVOW

Alvotech

Last Close

12.66

08/11 21:00

Market Cap

3.65B

Beta: -

Volume Today

57.66K

Avg: -

PE Ratio

−5.85

PFCF: −11.61

Preview